Merriman Wealth Management LLC Takes Position in ChromaDex Co. (NASDAQ:CDXC)

Merriman Wealth Management LLC bought a new stake in ChromaDex Co. (NASDAQ:CDXC) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 11,800 shares of the company’s stock, valued at approximately $32,000.

Other institutional investors have also added to or reduced their stakes in the company. WINTON GROUP Ltd bought a new stake in shares of ChromaDex during the second quarter valued at approximately $597,000. SG Americas Securities LLC bought a new stake in ChromaDex during the 1st quarter valued at $54,000. Lazard Asset Management LLC acquired a new position in ChromaDex during the first quarter worth $43,000. Miracle Mile Advisors LLC bought a new position in shares of ChromaDex in the second quarter valued at $27,000. Finally, Acadian Asset Management LLC acquired a new position in shares of ChromaDex during the first quarter valued at about $67,000. 15.41% of the stock is owned by institutional investors and hedge funds.

ChromaDex Price Performance

NASDAQ CDXC opened at $3.63 on Friday. The company has a fifty day moving average price of $3.17 and a 200-day moving average price of $3.15. The firm has a market cap of $274.21 million, a price-to-earnings ratio of -72.60 and a beta of 1.86. ChromaDex Co. has a 1 year low of $1.25 and a 1 year high of $4.65.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of ChromaDex in a report on Friday, August 9th. Roth Mkm reissued a “buy” rating and issued a $6.00 price objective on shares of ChromaDex in a research note on Wednesday, June 12th.

Insider Buying and Selling

In other ChromaDex news, Director Kristin Patrick sold 23,000 shares of the stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $3.57, for a total value of $82,110.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 9.64% of the stock is owned by corporate insiders.

ChromaDex Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.